Three Cases of Massive Fetomaternal Hemorrhage Presenting Without Clinical Suspicion

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 4, 2004, Pages 463-465

  Pourbabak, Sam ^a   Rund, Chad R ^a   Crookston, Kendall P ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIGEN;

ADULT; ALLOIMMUNIZATION; ARTICLE; BLOOD VOLUME; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; FETUS MALFORMATION; FETUS MOVEMENT; HEART RHYTHM; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; OBSTETRICS; QUANTITATIVE ANALYSIS; SYMPTOMATOLOGY;

ADULT; ANEMIA; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; FEMALE; FETAL BLOOD; FETOMATERNAL TRANSFUSION; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PREGNANCY; RH ISOIMMUNIZATION; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN;

EID: 1842426835     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986;51:117-121.
2. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion. 1990;30:344-357.
3. ACOG practice bulletin. Prevention of Rh D alloimmunization. No. 4, May 1999 (replaces educational bulletin No. 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet. 1999;66:63-70.
4. Samadi R, Greenspoon JS, Gviazda I, Settlage RH, Goodwin TM. Massive fetomaternal hemorrhage and fetal death: are they predictable? J Perinatol. 1999; 19:227-229.
5. Rosenn B, Ben Chetrit A, Palti Z, Hurwitz A. Sinusoidal fetal heart rate pattern due to massive feto-maternal transfusion. Int J Gynaecol Obstet. 1990;31: 271-273.
6. Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists. Am J Clin Pathol. 1998;110:281-292.
7. Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv. 1997;52:372-380.
8. Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998;338:798-803.
9. Mills L, Napier JA. Massive feto-maternal haemorrhage: effect of passively administered anti-D in the prevention of Rh sensitization and haemolytic disease of the newborn. Br J Obstet Gynaecol. 1988;95:1007-1012.
10. Chen JC, Davis BH, Wood B, Warzynski MJ. Multicenter clinical experience with flow cytometric method for fetomaternal hemorrhage detection. Cytometry. 2002;50:285-290.
11. Kennedy GA, Shaw R, Just S, et al. Quantification of feto-maternal haemorrhage (FMH) by flow cytometry: anti-fetal haemoglobin labelling potentially underestimates massive FMH in comparison to labelling with anti-D. Transfus Med 2003;13:25-34.
12. Howard HL, Martlew VI, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynaecol. 1997;104:37-41.